Department of Radiation Oncology, Gazi University Medical Faculty, Ankara, Turkey.
Department of Radiation Oncology, Gazi University Medical Faculty, Ankara, Turkey.
J Surg Res. 2021 Jul;263:167-175. doi: 10.1016/j.jss.2021.01.033. Epub 2021 Mar 2.
The capsular contracture is one of the main complications after radiotherapy in patients with implant-based reconstruction. The aim of this study is to evaluate the efficacy of ramipril for the prevention of radiation-induced fibrosis around the silicone implant.
Thirty Wistar rats in 5 groups were used. Group 1: implant; group 2: implant + radiation; group 3: ramipril + implant; group 4: ramipril + implant + radiation; group 5: sham. Ramipril treatment was started 5 d before surgery and continued for 12 wk after surgery. A mini silicone implant was placed in the back of the rats. A single fraction of 21.5 Gy radiation was applied. Tissues were examined histologically and immunohistochemically (TGF-β1, MMP-2, and TIMP-2 expression). The alteration of plasma TGF-β1 levels was examined before and after the experiment.
After applying implant or implant + radiation, capsular thickness, percentage of fibrotic area, tissue and plasma TGF-β1 levels significantly increased, and MMP-2/TIMP-2 ratio significantly decreased compared with the sham group. In ramipril-treated groups, the decrease in capsular thickness, fibrosis, TGF-β1 positivity, and an increase in MMP-2/TIMP-2 ratio were found significant. In the ramipril + implant + radiation group, the alteration values of TGF-β1 dramatically decreased.
Our results show that ramipril reduces radiation-induced fibrosis and contracture. The results of our study may be important for the design of the clinical trials required to investigate the effective and safe doses of ramipril, which is an inexpensive and easily tolerated drug, on humans.
包膜挛缩是植入物重建后放疗的主要并发症之一。本研究旨在评估雷米普利预防硅酮植入物周围放射性纤维化的疗效。
将 30 只 Wistar 大鼠分为 5 组。第 1 组:植入物;第 2 组:植入物+放疗;第 3 组:雷米普利+植入物;第 4 组:雷米普利+植入物+放疗;第 5 组:假手术。雷米普利治疗于术前 5 天开始,术后持续 12 周。在大鼠背部放置微型硅胶植入物。给予单次 21.5Gy 放疗。组织学和免疫组织化学检查(TGF-β1、MMP-2 和 TIMP-2 表达)。实验前后检测血浆 TGF-β1 水平的变化。
与假手术组相比,植入物或植入物+放疗后,包膜厚度、纤维化面积百分比、组织和血浆 TGF-β1 水平显著增加,MMP-2/TIMP-2 比值显著降低。雷米普利治疗组发现包膜厚度、纤维化、TGF-β1 阳性率降低,MMP-2/TIMP-2 比值升高。在雷米普利+植入物+放疗组,TGF-β1 的变化值明显降低。
我们的研究结果表明,雷米普利可减少放疗引起的纤维化和挛缩。我们的研究结果可能对设计临床试验具有重要意义,以研究雷米普利在人类中的有效和安全剂量,雷米普利是一种廉价且易于耐受的药物。